{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:33:29Z","timestamp":1790706809879,"version":"4.1.0"},"reference-count":39,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,1,24]],"date-time":"2017-01-24T00:00:00Z","timestamp":1485216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["9962"],"award-info":[{"award-number":["9962"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["15925"],"award-info":[{"award-number":["15925"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Achieving complete remission (<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>) in childhood relapsed\/refractory acute lymphoblastic leukaemia (<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>) is a difficult task. Bortezomib, a proteasome inhibitor, has <jats:italic>in\u00a0vitro<\/jats:italic> activity against <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> blasts. A phase I\u2010<jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> trial, reported by the Therapeutic Advances in Childhood Leukaemia and Lymphoma (<jats:styled-content style=\"fixed-case\">TACL<\/jats:styled-content>) consortium, demonstrated that bortezomib with chemotherapy has acceptable toxicity and remarkable activity in patients with relapsed <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> failing 2\u20133 previous regimens. We evaluated bortezomib in combination with chemotherapy in 30 and 7 children with B\u2010cell precursor (<jats:styled-content style=\"fixed-case\">BCP<\/jats:styled-content>) and T\u2010cell <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>, respectively. Bortezomib (1\u00b73\u00a0mg\/m<jats:sup>2<\/jats:sup>\/dose) was administered intravenously on days 1, 4, 8, and 11. Chemotherapy agents were the same as those used in the <jats:styled-content style=\"fixed-case\">TACL<\/jats:styled-content> trial, consisting of dexamethasone, doxorubicin, vincristine and pegylated asparaginase. Three patients (8\u00b71%) died due to infections. Twenty\u2010seven patients (72\u00b79%) achieved <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content> or <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content> with incomplete platelet recovery (<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>p). Fourteen had minimal residual disease (<jats:styled-content style=\"fixed-case\">MRD<\/jats:styled-content>) lower than 0\u00b71%. Twenty\u2010two of 30 <jats:styled-content style=\"fixed-case\">BCP<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> patients (73\u00b73%) and 5\/7 patients (71%) with T\u2010cell <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> achieved <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>p. The 2\u2010year overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) is 31\u00b73%; <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>p patients with an <jats:styled-content style=\"fixed-case\">MRD<\/jats:styled-content> response had a remarkable 2\u2010year <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> of 68\u00b74%. These data confirm that the combination of bortezomib with chemotherapy is a suitable\/effective option for childhood relapsed\/refractory <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/bjh.14505","type":"journal-article","created":{"date-parts":[[2017,1,24]],"date-time":"2017-01-24T08:02:46Z","timestamp":1485244966000},"page":"629-636","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["The combination of bortezomib with chemotherapy to treat\u00a0relapsed\/refractory acute lymphoblastic leukaemia of childhood"],"prefix":"10.1111","volume":"176","author":[{"given":"Alice","family":"Bertaina","sequence":"first","affiliation":[{"name":"Department of Paediatric Haematology\u2010Oncology IRCCS Ospedale Pediatrico Bambino Ges\u00f9 Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Vinti","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology\u2010Oncology IRCCS Ospedale Pediatrico Bambino Ges\u00f9 Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Strocchio","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology\u2010Oncology IRCCS Ospedale Pediatrico Bambino Ges\u00f9 Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Gaspari","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology\u2010Oncology IRCCS Ospedale Pediatrico Bambino Ges\u00f9 Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Caruso","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology\u2010Oncology IRCCS Ospedale Pediatrico Bambino Ges\u00f9 Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Algeri","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology\u2010Oncology IRCCS Ospedale Pediatrico Bambino Ges\u00f9 Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Coletti","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology\u2010Oncology IRCCS Ospedale Pediatrico Bambino Ges\u00f9 Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Gurnari","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology\u2010Oncology IRCCS Ospedale Pediatrico Bambino Ges\u00f9 Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Romano","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology\u2010Oncology IRCCS Ospedale Pediatrico Bambino Ges\u00f9 Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giuseppina","family":"Cefalo","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology\u2010Oncology IRCCS Ospedale Pediatrico Bambino Ges\u00f9 Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Girardi","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology\u2010Oncology IRCCS Ospedale Pediatrico Bambino Ges\u00f9 Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Trevisan","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology\u2010Oncology IRCCS Ospedale Pediatrico Bambino Ges\u00f9 Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Bertaina","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology\u2010Oncology IRCCS Ospedale Pediatrico Bambino Ges\u00f9 Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Merli","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology\u2010Oncology IRCCS Ospedale Pediatrico Bambino Ges\u00f9 Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology\u2010Oncology IRCCS Ospedale Pediatrico Bambino Ges\u00f9 Rome Italy"},{"name":"Department of Paediatrics University of Pavia Pavia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,1,24]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4626"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.6065"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05947-11"},{"key":"e_1_2_8_5_1","first-page":"203","article-title":"Morphoproteomics and bortezomib\/dexamethasone\u2010induced response in relapsed acute lymphoblastic leukemia","volume":"34","author":"Brown R.E.","year":"2004","journal-title":"Annals of Clinical and Laboratory Science"},{"key":"e_1_2_8_6_1","article-title":"Management and treatment of Magnusiomyces capitatus (Geotrichum capitatum) pleural infection in a non\u2010neutropenic patient with posaconazole. A new therapeutic opportunity?","volume":"10","author":"Brunetti G.","year":"2016","journal-title":"New Microbiologica"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6361"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcl.2014.09.006"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.10.7.15067"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12508"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.23415"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.59"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.08.006"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05773.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70017-8"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.08072.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-005-0135-z"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-1953-4"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0170"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0871"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.2950"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.366"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1086\/649879"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-265884"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22456"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-418640"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4541"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.698273"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.227"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62002-8"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052603"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.2679"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.09.020"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.1983"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1175-6"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14505","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.14505","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T03:14:17Z","timestamp":1696302857000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,24]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1111\/bjh.14505"],"URL":"https:\/\/doi.org\/10.1111\/bjh.14505","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,24]]},"assertion":[{"value":"2016-08-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-10-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-01-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}